Your browser doesn't support javascript.
loading
Clinical features and drug selection in 54 patients with inflammatory bowel disease and comorbid autoimmune disease / 中华消化杂志
Chinese Journal of Digestion ; (12): 681-685, 2016.
Article in Chinese | WPRIM | ID: wpr-502543
ABSTRACT
Objective To explore the differences in disease location,pathological feature,disease severity,extraintestinal manifestations and drug treatment between inflammatory bowel disease (IBD) patients with comorbid autoimmune disease (AD) and simple IBD patients.Methods From January 2009 to December 2014,the clinical data of 54 IBD patients with comorbid AD and at the same period 74 simple hospitalized IBD patients were retrospectively analyzed.According to IBD type and whether combined with AD,patients were divided into Crohn's disease (CD)+AD group (n=16),CD group (n=26),ulcerative colitis (UC)+AD group (n=38) and UC group (n=48).Chi square test was performed to compare the differences in disease severity,location,extraintestinal manifestations and drug treatment between IBD patients with and without AD.Results There was no statistically significant difference in location among four groups (all P>0.05).The most common concomitant AD of IBD was rheumatoid arthritis (20.4%,11/54) and ankylosing spondylitis (13.0%,7/54).The proportion of mild active patients of CD+ AD group was lower than that of CD group (2/16 vs 53.8% (14/26),x2 =7.180,P=0.007),while the proportion of severe active patients was significantly higher that of CD group (6/16 vs 0,x2 =8.519,P=0.004).There was no statistically significant difference in moderate active patients between the two groups (P=0.808).Main type of patients of UC+ AD group (76.3 %,29/38) and UC group (68.8 %,33/48) were moderate active patients.There was no statistically significant difference in disease stage and location (all P>0.05).The incidence of extraintestinal manifestations of IBD+AD group (55.6 %,30/ 54) was significantly higher than that of IBD group (9.5 %,7/74,x2 =32.279,P<0.01),and the main manifestation was arthritis (37.0% (20/54) vs 5.4% (4/74),x2=20.504,P<0.01).The rate of glucocorticoid and immunosuppressant application in IBD+AD group was higher than that of IBD group (40.7% (22/54) vs 17.6%(13/74),x2 =8.438,P=0.004;20.4%(11/54) vs 0,x2=14.000,P< 0.01).Conclusions The condition of patients with IBD and comorbid AD is more severe,and the incidence of extraintestinal manifestations is higher.Early treated with glucocorticoid and immunosuppressant could effectively achieve remission.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Digestion Year: 2016 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Chinese Journal of Digestion Year: 2016 Type: Article